Authorized purpose: Visualizes hepatic vasculature and identifies arteries near hypervascular liver lesions during planning of liver embolization.
Clinical role
Post-processing software for liver 3D X-ray angiography (CBCT) images that semi-automatically segments the liver arterial tree from an operator-defined starting point; its output is an adjunct physicians may use to evaluate hepatic arterial anatomy when planning embolization procedures.
Images and patients
Fluoroscopy/Angiography · Liver; hepatic arterial vasculature and hypervascular liver lesions
Key limitation
Keep in mind: Adjunct for the planning phase of liver embolization; pediatric applicability is unknown from the supplied FDA packet.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Visualizes hepatic vasculature and identifies arteries near hypervascular liver lesions during planning of liver embolization.
Which images or clinical context are in scope?Modality: Fluoroscopy/Angiography Anatomy or clinical context: Liver; hepatic arterial vasculature and hypervascular liver lesions Input: Contrast-injected 3D X-ray angiography or CBCT liver images; other studies may be reviewed side by side but are not the primary catalog modality.
Who uses it?Intended users: Physicians.
What does the software produce?Output: Liver and arterial-tree segmentation and visualization, lesion-vicinity vessel identification, Live Tracking, estimated distal liver region or Virtual Parenchyma, and optional saved or exported results.
What is its most important limitation?Key limitation: Adjunct for the planning phase of liver embolization; pediatric applicability is unknown from the supplied FDA packet.
Clinical takeaway. Clinical role: Visualizes hepatic vasculature and identifies arteries near hypervascular liver lesions during planning of liver embolization.
Evidence takeaway. Evidence from the reviewed source record: FDA-reported design-control and bench testing plus clinical assessment of paired CBCT studies by interventional radiologists using a five-point Likert scale; no sensitivity or specificity endpoint was stated.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Visualizes hepatic vasculature and identifies arteries near hypervascular liver lesions during planning of liver embolization.
Exact FDA submission
Checked 2026-09-19
Clinical-use display mirrors the exact FDA-supported purpose reconciled in this remediation finding.
Post-processing software for liver 3D X-ray angiography (CBCT) images that semi-automatically segments the liver arterial tree from an operator-defined starting point; its output is an adjunct physicians may use to evaluate hepatic arterial anatomy when planning embolization procedures.
Exact FDA submission
Checked 2026-11-14
Packet wording: "FlightPlan for Liver is a post processing software package that helps the analysis of 3D X-ray angiography images of the liver." … "Semi‐automatic segmentation of the liver arterial tree from an operator‐defined starting point in the CBCT images.". Read from the exact FDA decision document on 2026-11-14.
Liver and arterial-tree segmentation and visualization, lesion-vicinity vessel identification, Live Tracking, estimated distal liver region or Virtual Parenchyma, and optional saved or exported results.
FDA-reported design-control and bench testing plus clinical assessment of paired CBCT studies by interventional radiologists using a five-point Likert scale; no sensitivity or specificity endpoint was stated.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA-reported design-control and bench testing plus clinical assessment of paired CBCT studies by interventional radiologists using a five-point Likert scale; no sensitivity or specificity endpoint was stated.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
Liver ASSIST Virtual Parenchyma regulatory performance study summary
DesignStand-Alone Performance
PopulationAdult
Scopeexact submission
Tested versionvxtl_17.0-4.24
IndependenceIndependence not established
K210807
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K210807. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Contrast-injected 3D X-ray angiography or CBCT liver images; other studies may be reviewed side by side but are not the primary catalog modality.
Scope: Exact FDA submission. FDA packet primary and secondary image scope.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The exact FDA package describes CBCT images as input, saving of results with optional export to GE's Vision application for 3D road-mapping, and compliance with the NEMA PS 3.1-3.20 (2016) DICOM standard. Interface versions and local compatibility require confirmation.
Scope: Exact FDA submission. Packet wording: "is a post‐processing, software‐only application using 3D X‐ray angiography images (CBCT) as input." … "Saving of results and export optionally to GE’s Vision application [K092639] for 3D road‐mapping.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes FlightPlan for Liver as post-processing software that operates on GE's Advantage Workstation and AW Server platforms as an extension to the Volume Viewer application. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "is a post‐processing, software‐only application using 3D X‐ray angiography images (CBCT) as input." … "The software operates on GE’s Advantage Workstation [K110834] platform and AW Server [K081985] platform and is an extension to the GE’s Volume Viewer application". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Liver and arterial-tree segmentation and visualization, lesion-vicinity vessel identification, Live Tracking, estimated distal liver region or Virtual Parenchyma, and optional saved or exported results.
Scope: Exact FDA submission. FDA packet output scope.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Liver and arterial-tree segmentation and visualization, lesion-vicinity vessel identification, Live Tracking, estimated distal liver region or Virtual Parenchyma, and optional saved or exported results.
Scope: Exact FDA submission. FDA packet output scope.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes FlightPlan for Liver as post-processing software that operates on GE's Advantage Workstation and AW Server platforms as an extension to the Volume Viewer application. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "is a post‐processing, software‐only application using 3D X‐ray angiography images (CBCT) as input." … "The software operates on GE’s Advantage Workstation [K110834] platform and AW Server [K081985] platform and is an extension to the GE’s Volume Viewer application". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
The exact FDA package describes CBCT images as input, saving of results with optional export to GE's Vision application for 3D road-mapping, and compliance with the NEMA PS 3.1-3.20 (2016) DICOM standard. Interface versions and local compatibility require confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "is a post‐processing, software‐only application using 3D X‐ray angiography images (CBCT) as input." … "Saving of results and export optionally to GE’s Vision application [K092639] for 3D road‐mapping.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
ACR AI Central provides an exact-submission model card for FlightPlan for Liver; FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
27Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, fda decision summary packet, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission
No public price or quote for the exact K210807 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not verified - checked 2026-09-09 - Exact FDA submission
Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-09 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-09 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: Cydar EV provides image guidance by overlaying preoperative 3D vessel anatomy from a previously acquired contrast-enhanced diagnostic CT scan onto live fluoroscopic images to assist positioning guidewires, catheters, and other endovascular devices. It is intended for fluoroscopy-guided endovascular procedures in the lower thorax, abdomen, and pelvis, including AAA and mid-distal TAA repair, angioplasty, stenting, and embolization in specified iliac arteries and corresponding veins, and is not intended for liver, kidney, or pelvic-organ procedures.
Modality
Fluoroscopy/Angiography
Anatomy
Lower thorax, abdomen, and pelvis; iliac vessels and corresponding veins
Authorized purpose: OrthoGrid Hip AI 4.0 analyzes two-dimensional C-arm fluoroscopic images to assist positioning of hip-replacement components during direct-anterior total hip arthroplasty.
Authorized purpose: Canon Intelligent NR is a noise-reduction function for fluoroscopic images acquired on compatible Canon radiography and fluoroscopy systems.
Authorized purpose: Trinias is an interventional fluoroscopic X-ray system for diagnostic and interventional angiography, including cardiac, neurovascular, abdominal, peripheral, rotational, multipurpose, and whole-body radiographic or fluoroscopic procedures.
Modality
Fluoroscopy/Angiography
Anatomy
Heart, neurovascular, abdominal, peripheral vessels, and whole body
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.